Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

被引：0
|
作者：
Sandhu, Shahneen Kaur
Violet, John A.
Ferdinandus, Justin
Thang, Sue-Ping
Iravani, Amir
Guo, Christina
Kong, Grace
Kumar, Aravind Ravi
Akhurst, Timothy J.
Beaulieu, Alexis
Murphy, Declan G.
Mooi, Jennifer
Tran, Ben
Toner, Guy C.
Williams, Scott
Hicks, Rodney J.
Hofman, Michael
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Canc Imaging, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Dept Canc Surg, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5040
引用
收藏
页数：1
相关论文
共 50 条
  • [1] High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
    Hofman, Michael
    Violet, John
    Sandhu, Shahneen
    Ferdinandus, Justin
    Thang, Sue Ping
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Tim
    Jackson, Price
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [2] Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
    Hofman, Michael
    Violet, John A.
    Hicks, Rodney J.
    Ferdinandus, Justin
    Thang, Sue Ping
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Timothy J.
    Mooi, Jennifer
    Guo, Christina
    Tran, Ben
    Jackson, Price
    Scalzo, Mark
    Eu, Peter
    Williams, Scott
    Sandhu, Shahneen Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
    Hofman, M. S.
    Sandhu, S.
    Eu, P.
    Price, J.
    Akhurst, T.
    Iravani, A.
    Kong, G.
    Ravi-Kumar, A.
    Williams, S.
    Thang, S-P.
    Murphy, D.
    Scalzo, M.
    Hicks, R. J.
    Violet, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
    Ranjan, Satish Kumar
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (03) : 227 - 228
  • [5] Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Dwabe, Sami
    Yazdanpanah, Omid
    Warnecke, Brian
    Benjamin, David Joseph
    Rezazadeh, Arash
    Mar, Nataliya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
    Patell, Kanchi
    Kurian, Matthew
    Garcia, Jorge A.
    Mendiratta, Prateek
    Barata, Pedro C.
    Jia, Angela Y.
    Spratt, Daniel E.
    Brown, Jason R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (07) : 731 - 744
  • [7] Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Rami, Avina
    Ng, Thomas S. C.
    Rothmann, Emily
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Choudhury, Atish Dipankar
    Gao, Xin
    Haberman, Veronica
    Kako, Bashar
    Kilbridge, Kerry L.
    Morgans, Alicia K.
    O'Shea, Aileen
    Taplin, Mary-Ellen
    Jacene, Heather
    Ravi, Praful
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 27 - 27
  • [8] Lutetium-177 labelled prostate-specific membrane antigen (PSMA) for metastatic castrate-resistant prostate cancer (MCRPC): a systematic review and meta-analysis
    Calopedos, R.
    Chalasani, V.
    Asher, R.
    Emmett, L.
    Woo, H.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 110 - 110
  • [9] A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
    Crumbaker, Megan
    Joshua, Anthony M.
    Epstein, Richard
    Emmett, Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2020, 203 (05): : 882 - 882
12345